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Objectives: Selective digestive decontamination (SDD) and selective oropharyngeal decontamination
(SOD) improved intensive care unit (ICU), hospital and 28-day survival in ICUs with low levels of anti-
biotic resistance. Yet it is unclear whether the effect differs between medical and surgical ICU patients.
Methods: In an individual patient data meta-analysis, we systematically searched PubMed and included
all randomized controlled studies published since 2000. We performed a two-stage meta-analysis with
separate logistic regression models per study and per outcome (hospital survival and ICU survival) and
subsequent pooling of main and interaction effects.
Results: Six studies, all performed in countries with low levels of antibiotic resistance, yielded 16 528
hospital admissions and 17 884 ICU admissions for complete case analysis. Compared to standard care or
placebo, the pooled adjusted odds ratios for hospital mortality was 0.82 (95% conﬁdence interval (CI)
0.72e0.93) for SDD and 0.84 (95% CI 0.73e0.97) for SOD. Compared to SOD, the adjusted odds ratio for
hospital mortality was 0.90 (95% CI 0.82e0.97) for SDD. The effects on hospital mortality were not
modiﬁed by type of ICU admission (p values for interaction terms were 0.66 for SDD and control, 0.87 for
SOD and control and 0.47 for SDD and SOD). Similar results were found for ICU mortality.
Conclusions: In ICUs with low levels of antibiotic resistance, the effectiveness of SDD and SOD was not
modiﬁed by type of ICU admission. SDD and SOD improved hospital and ICU survival compared to
standard care in both patient populations, with SDD being more effective than SOD. N.L. Plantinga, Clin
Microbiol Infect 2018;24:505
© 2017 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Selective decontamination is a widely used infection prevention
strategy in Dutch intensive care units (ICUs). The concept entailsf the European Congress of
t O387).
ter for Health Sciences and
eidelberglaan 100, 3584 CX
Plantinga).
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).the preventive use of a mixture of topical antimicrobial agents with
activity against aerobic Gram-negative bacteria, Staphylococcus
aureus and yeasts to eradicate and prevent carriage with these
pathogens, thereby preventing ICU-acquired infections. Selective
oropharyngeal decontamination (SOD) consists of an oropharyn-
geal paste, usually containing tobramycin, colistin and amphoter-
icin B, administered 4 times a day. Selective digestive
decontamination (SDD) contains the same paste, supplemented
with a suspension (with the same antimicrobial agents) adminis-
tered through the nasogastric tube and a 4-day course of intrave-
nously administered cephalosporins (usually cefotaxime). Theof Clinical Microbiology and Infectious Diseases. This is an open access article under
N.L. Plantinga et al. / Clinical Microbiology and Infection 24 (2018) 505e513506effects on patient outcome have been extensively investigated in
ICUs with low levels of antibiotic resistance and include a reduction
in ICU mortality, hospital mortality, 28-day mortality and ICU-
acquired bacteraemia [1e3]. The two largest, and most recent,
studies compared the effectiveness of SDD and SOD, with a sig-
niﬁcant survival beneﬁt for SDD in one study [4] and a comparable
effect in the other [1].
ICUs admit patients with large differences in age, reason for
admission and disease severity, and thereby host a markedly het-
erogeneous population. It has been advocated that the (beneﬁcial)
effects of treatment should be investigated in more depth to
identify those groups of patients who may beneﬁt and those who
may not beneﬁt at all [5]. For SDD and SOD, it is unknownwhether
its effectiveness differs between surgical and medical patients, as
the pathology and disease severity at ICU admission may vary be-
tween these two groups. Medical patients have on average longer
hospitalization before ICU admission, and surgical patients more
frequently have delayed intestinal passage. These characteristics
may differently affect the capacity of SDD and SOD to eradicate
existing and prevent new bacterial carriage and thus the effec-
tiveness of these interventions in both patient groups.
In a traditional meta-analysis of 21 trials published between
1987 and 1996, SDD was associated with lower mortality and
nosocomial infection rates in ICUs in which at least 75% of the
patients included in the studies had been admitted after trauma or
major surgery (11 studies), but not in ICUs inwhich less than 75% of
admitted patients were categorized as having experienced trauma
or major surgery (ten studies) [6]. In a subgroup analysis by the
Dutch SOD-SDD Trialists' Group, SOD was associated with
improved 28-day survival in the subgroup of nonsurgical patients
only, whereas SDD was not associated with a difference in effec-
tiveness between surgical and nonsurgical patients [7]. New and
large studies have been performed since 1996, and the subgroup
analysis mentioned originated from a single study that has not yet
been replicated. In an individual patient datameta-analysis, there is
more ﬂexibility and power to examine whether treatment effects
differ between subgroups. Furthermore, it avoids ecologic bias,
which can be present when examining subgroups using meta-
regression based on aggregate data [8,9].
We therefore performed an individual patient data meta-
analysis to determine whether the effects of SDD and SOD differ
between surgical and medical patients.
Methods
Data collection
We performed an individual patient data meta-analysis and
included randomized controlled trials (RCTs) and cluster random-
ized trials (CRTs) with crossover that were performed in mixed
adult ICUs and that were published between 2000 and 2016
(Supplementary Fig. 1). We excluded studies that only admitted
either trauma, surgical or medical patients because these did not
allow assessment of effect modiﬁcation (also known as interaction)
by admission type, as well as studies in paediatric or very speciﬁc
ICU populations. Studies were identiﬁed through a systematic
PubMed search including synonyms for domain, determinant and
design without language restrictions or ﬁlters (9 March 2017).
References of three previous meta-analyses were checked for
missed trials [10e12]. First authors were asked to share a minimal
set of individual patient data, including age, sex, disease severity,
admission type and information on at least one of the two
outcomes.
Our primary outcome was hospital survival, and the secondary
outcome was ICU survival. From each study, we included all ICUadmissions of patients who had received the intervention or con-
trol measure at least once (intention to treat) and performed a
complete case analysis. For both outcomes, comparisons were
made among SDD, SOD and patients who had received either pla-
cebo or standard care (control group). The analysis for hospital
survival was limited to the ﬁrst inclusion within each hospital
admission. The classiﬁcation of patients into surgical and medical
admissions was performed according to the original study deﬁni-
tions (Table 1). Trauma patients for whom it was unknownwhether
they had undergone surgery were reclassiﬁed as surgical admis-
sions. To be included, ethical permission had to have been obtained
within each individual study.Statistical analysis
We performed a two-stage meta-analysis in which we ﬁrst
performed a separate logistic regression analysis within each study
and for each outcome. Within each of these analyses, two models
were ﬁtted, one with an interaction between treatment and
admission type to assess whether the effect of SDD and SOD
differed betweenmedical and surgical admissions, and onewithout
this interaction term to estimate the main effect of SDD and SOD.
These logistic models per study were stratiﬁed for study centre (as
separate intercepts), thereby correcting for clustering. Because of
the possibility of differences in baseline characteristics in cluster
randomized trials, we also adjusted for age, sex, admission type
(medical or surgical) and Acute Physiology and Chronic Health
Evaluation (APACHE) II/IV score, as well as, when available, me-
chanical ventilation at ICU admission by adding these as main ef-
fects to the model. The estimated treatment effects from each study
were meta-analysed in the second stage. We used random-effects
or ﬁxed-effect (depending on the degree of heterogeneity) meta-
analytical techniques to obtain a pooled treatment effect across
studies using inverse variance weighting. Heterogeneity in main
treatment and interaction effects were assessed visually using
forest plots and the I2 statistic.
SPSS Statistics 21 (IBM SPSS, Chicago, IL, USA) was used for
preparation of the data set, and RStudio 0.99.903 (https://www.
rstudio.com/) was used for statistical analysis (packages lme4
[13], mvmeta [14] and metaphor [15]) (R; R Foundation for Statis-
tical Computing, Vienna, Austria; http://www.r-project.org/).Results
Included studies
The PubMed search yielded 265 articles published between
2000 and 2016, of which six original studies were eligible for in-
clusion (Supplementary Fig. 1). All authors provided individual
patient data (Table 1). In four RCTs, either SDD or SOD was
compared to a control intervention [2,3,16,17], in one CRT a com-
parison between all three arms was performed and in the largest
CRT SOD and SDD were compared head to head [1,4]. Three studies
were blinded [3,16,17] and the other studies [1,2,4] had a cluster
design, which excludes the possibility of blinding but prevents the
occurrence of contamination (i.e. treated patients protecting con-
trol patients from acquired colonization and infection). In total 29
different hospitals from three different countries participated in
these studies, eight of which took part in two studies. Sample sizes
ranged from 226 to 9206 hospital admissions and 9773 ICU ad-
missions per study. Information on hospital survival was not
available from two RCTs; for one study, 60-day survival status was
used as proxy (for ICU survivors) [3]; the other study was excluded
from the analysis of hospital survival [17].
Table 1
Study characteristics
Study Bergmans 2001 [16] Krueger 2002 [3] De Jonge 2003 [2] Camus 2005 [17] De Smet 2009 [1] Oostdijk 2017 [4] a
DOI 10.1164/ajrccm.164.3.2005003 10.1164/rccm.2105141 10.1016/S0140-6736
(03)14409-1
10.1097/01.CCM.
0000152224.01949.01
10.1056/NEJMoa0800394 10.1001/jama.2017.1282
Country The Netherlands Germany The Netherlands France The Netherlands The Netherlands
Design RCT, double blind RCT, double blind
(randomization stratiﬁed
by APACHE II)
RCT, nonblinded (individual
randomization to unit)
RCT, double blind
(4  4 factorial design)
CRT with crossover CRT with crossover
Control group Placebo Placebo Standard care Placebo/placebo; placebo/
mupirocin nasal ointment
Standard care NA
SOD antibiotics GEN, CST, VAN NA NA NA TOB, CST, Amph B TOB, CST, Amph B
SDD antibiotics NA GEN, CST; CIP iv TOB, CST, Amph B; CTX iv CST, TOB/placebo;
CST, TOB/mupirocin nasal
ointment (no iv component)
TOB, CST, Amph B; CTX iv TOB, CST, Amph B; CTX or CRO iv
No. of hospitals 2 2 1 3 13 16
Inclusion period Sep 1994eDec 1996 Apr 1990eAug 1992 Sep 1999eDec 2001 Apr 1996eOct 1998 May 2004eJul 2006 Aug 2009eFeb 2013
Inclusion criteria
(original)
Intubation within 24 hours,
expected MV >2 days and
age 16 years; evaluable
if >2 days in study
Expected ICU LOS >48 hours,
age 18 years, at least
one additional conditionb
Expected MV >48 hours
or expected ICU LOS
>72 hours (adults)
Expected MV >48 hours,
intubated <48 hours at
inclusion, age 18 years
Expected MV >48 hours or
expected ICU LOS >72 hours
Expected ICU LOS >48 hours;
evaluable if patient received
at least one dose and/or had
an ICU LOS of >48 hours
Deﬁnition of
‘surgical admission’
Reason for ICU admission
was postoperative/surgical
(according to treating ICU
physician); ‘trauma’ was
recoded into surgical
admission
‘postoperative patient’ According to NICE criteria;
surgery in week before
ICU admission
Those admitted to ICU
immediately after surgery
from operating room;
‘trauma’ was recoded into
surgical admission
Reason for ICU admission was
postoperative/surgical according
to treating ICU physician
Received any type of surgery
in week before ICU admission
No. of ICU admissions
(complete cases)
226 (226) 527 (527) 934 (926) 515 (515) 5923 (5914) 9773 (9768)
No. of hospital admissions
(complete cases)
226 (226) 527 (527) 933 (925) 515 (0) 5650 (5643) 9206 (9201)
Amph B, amphotericin B; APACHE, Acute Physiology and Chronic Health Evaluation (measure of disease severity); CIP, ciproﬂoxacin; CRO, ceftriaxone; CRT, cluster randomized trial; CST, colistin; CTX, cefotaxime; GEN,
gentamicin; ICU, intensive care unit; MV, mechanical ventilation; NA, not applicable; NICE, Nationale Intensive Care Evaluatie (www.stichting-nice.nl); RCT, randomized controlled trial; SDD, selective digestive decontami-
nation; SOD, selective oropharyngeal decontamination; TOB, tobramycin; VAN, vancomycin.
a This is only study with APACHE IV instead of APACHE II, without a control group and without information on ventilation at baseline (MV).
b Additionally, at least one of following conditions had to be present: expected intubation period of more than 24 hours, respiratory failure (PaO2 of <55 mm Hg on room air), thoracic or abdominal surgery within preceding
24 hours, severe organ dysfunction at admission, increased risk of aspiration caused by swallowing disorder, chronic obstructive pulmonary disease, immunosuppressive therapy or advanced age (>70 years).
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Table 2
Patient characteristics per ﬁrst inclusion within unique hospital admission, including incomplete cases (n ¼ 14 for main models; n ¼ 22 for model effect modiﬁcation)
Characteristic SDD, n (%) (n ¼ 7718) SOD, n (%) (n ¼ 6326) Control, n (%) (n ¼ 3013)
Men, n (%) 4699 (60.9) 3918 (61.9) 1853 (61.6)
Age, years, mean (SD)tbl2fna 62.3 (16.0) 62.3 (15.9) 60.3 (16.8)
APACHE II score, mean (SD)a 19.5 (7.7) 19.6 (8.2) 19.0 (7.8)
APACHE IV score, mean (SD)b 81.7 (33.8) 82.1 (33.4) NA
SAPS II score, mean (SD)c 46.5 (15.3) NA 45.0 (14.4)
Mechanical ventilation at baseline, n (%)d 2698 (91.6) 1788 (94.5) 2699 (89.6)
Medical admissions, n (%) 4522 (58.6) 3841 (60.7) 1494 (49.7)
Surgical admissions, n (%) 3193 (41.4) 2485 (39.3) 1514 (50.3)
Study describing patient origin, n (%)
Bergmans [16] 87 (1.4) 139 (4.6)
Krueger [3] 265 (3.4) 262 (8.7)
De Jonge [2] 466 (6.0) 467 (15.5)
Camus [17] e 259 (3.4) 256 (8.5)
De Smet [1] 1955 (25.3) 1806 (28.5) 1889 (62.7)
Oostdijk [4] 4773 (61.8) 4433 (70.1)
APACHE, Acute Physiology and Chronic Health Evaluation (measure of disease severity); NA, not applicable; SAPS, Simpliﬁed Acute Physiology Score (measure of disease
severity); SD, standard deviation; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination.
a Not available from studies of Oostdijk et al. [4] and Camus et al. [17].
b Only available from Oostdijk et al. [4].
c Only available from Camus et al. [17].
d Not available from Oostdijk et al. [4].
e This study was not included in analysis on hospital survival.
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comprising 16 528 hospital admissions and 17 884 ICU admissions
from 16 540 unique patients available for complete case analysis
(Supplementary Fig. 2). There were slight imbalances in baseline
characteristics, which were partly due to imbalances between
study groups in some of the studies and partly due to differences
between studies, as ﬁve studies did not have all three treatment
arms (Table 2). There were 9857 hospital admissions (57.8%) with a
medical and 7192 (42.2%) with a surgical reason for ICU admission.Hospital mortality
Crude hospital mortality was 29.5% (2199/7458) for SDD, 31.5%
(1994/6326) for SOD and 32.4% (894/2756) among control groups
(Table 3). The main treatment effects and the interaction terms of
individual studies were fairly similar within each comparison,Table 3
Hospital and ICU mortality in all patients and in surgical and medical patients (two-stag
Mortality Crude mortality aOR (
SDD SOD Control SDD
Hospital mortalitya
Main (n 16 540) 2199/7458, 29.5% 1994/6326, 31.5% 894/2756, 32.4% 0.82
Medical (n 9417) 1423/4298, 33.1% 1322/3841, 34.4% 472/1278, 36.9% 0.84
Surgical (n 7115) 774/3157, 24.5% 672/2485, 27.0% 422/1473, 28.6% 0.79
Measure of interaction on multiplicative scale: ratio of aORs (95% CI),
surgical vs. medical
0.95
ICU mortality
Main (n 17 898) 1683/8086, 20.8% 1537/6701, 22.9% 753/3111, 24.2% 0.74
Medical (n 10 507) 1161/4810, 24.1% 1048/4137, 25.3% 419/1560, 26.9% 0.81
Surgical (n 7383) 520/3273, 15.9% 489/2564, 19.1% 334/1546, 21.6% 0.64
Measure of interaction on multiplicative scale: ratio of aORs (95% CI)
surgical vs. medical
0.82
aOR, adjusted OR; APACHE, Acute Physiology and Chronic Health Evaluation; CI, conﬁdenc
(calculated using pooled aORs and overall proportion of patients who died in comparator
mortality risks, NNT may be different)); SDD, selective digestive decontamination; SOD,
a For SDD vs. control analysis on hospital mortality includes three and on ICUmortality
same studies.
b Models of multicentre studies were corrected for centre; models of cluster randomize
IV score and, when available, mechanical ventilation at ICU admission.with largely overlapping conﬁdence intervals (Figs. 1 and 2, I2
statistic 1%). One exception included the comparison of SDD vs.
SOD (main effect), where an adjusted odds ratio (aOR) of 1.01 was
found in the ﬁrst and an aOR of 0.85 in the second study (Fig. 3, I2
statistic 72.4%). Because the number of studies was limited, all
estimates were pooled using inverse variance weighting with
ﬁxed effects. Resulting aORs (95% conﬁdence intervals (CIs)) for
hospital mortality were 0.82 (0.72e0.93) for SDD vs. control, 0.84
(0.73e0.97) for SOD vs. control and 0.90 (0.82e0.97) for SDD vs.
SOD (Table 3, Figs. 1e3). Interactions between treatment and
admission type were not statistically signiﬁcant within each of the
three comparisons, as illustrated by adjusted relative odds ratios
(aRORs) (95% CIs) for surgical vs. medical patients for SDD vs.
control of 0.95 (0.74e1.21, p 0.66), for SOD vs. control of 1.03
(0.77e1.37, p 0.87) and for SDD vs SOD of 0.94 (0.79e1.11, p 0.47)
(Table 3, Figs. 1e3).e meta-analysis, ﬁxed pooled effect)
95% CI) for:b
vs. control SOD vs. control SDD vs. SOD
(0.72e0.93); NNT 23.7 0.84 (0.73e0.97); NNT 26.9 0.90 (0.82e0.97); NNT 43.2
(0.71e1.00); NNT 25.4 0.83 (0.68e1.01) 0.91 (0.82e1.01)
(0.66e0.94); NNT 22.0 0.85 (0.68e1.05) 0.87 (0.76e1.00); NNT 37.3
(0.74e1.21); p 0.66 1.03 (0.77e1.37); p 0.87 0.94 (0.79e1.11); p 0.47
(0.65e0.84); NNT 19.4 0.85 (0.73e1.00); NNT 35.7 0.86 (0.78e0.94); NNT 38.2
(0.68e0.95); NNT 24.8 0.93 (0.75e1.14) 0.89 (0.80e0.99); NNT 45.9
(0.53e0.79); NNT 15.3 0.77 (0.61e0.97); NNT 24.1 0.80 (0.69e0.93); NNT 31.0
(0.62e1.08); p 0.15 0.83 (0.61e1.14); p 0.25 0.89 (0.74e1.08); p 0.25
e interval; ICU, intensive care unit; LOS, length of stay; NNT, number needed to treat
group (control for ﬁrst two comparisons and SOD for latter; in settings with different
selective oropharyngeal decontamination.
four studies; for SOD vs. control and SDD vs. SOD, analyses on both outcomes include
d trials were corrected for age, sex, admission type (medical or surgical), APACHE II/
Fig. 1. Forest plots of effects of SDD on hospital mortality: pooled treatment effects and interaction terms (treatment with admission type).
*Surgical vs. medical; aOR, adjusted odds ratio; aROR, adjusted relative odds ratio; SOD, selective oropharyngeal decontamination; SDD, selective digestive decontamination.
Fig. 2. Forest plots of effects of SOD on hospital mortality: pooled treatment effects and interaction terms (treatment with admission type).
*Surgical vs. medical; aOR, adjusted odds ratio; aROR, adjusted relative odds ratio; SOD, selective oropharyngeal decontamination; SDD, selective digestive decontamination.
Fig. 3. Forest plots of effects of SDD compared to SOD on hospital mortality: pooled treatment effects and interaction terms (treatment with admission type).
*Surgical vs. medical; aOR, adjusted odds ratio; aROR, adjusted relative odds ratio; SOD, selective oropharyngeal decontamination; SDD, selective digestive decontamination.
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Fig. 4. Forest plots of effects of SDD and SOD on ICU mortality: pooled treatment effects and interaction terms (treatment with admission type).
*Surgical vs. medical; aOR, adjusted odds ratio; aROR, adjusted relative odds ratio; SOD, selective oropharyngeal decontamination; SDD, selective digestive decontamination.
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Crude ICU mortality was 20.8% (2199/7458) for SDD, 22.9%
(1994/6326) for SOD and 24.2% (894/2756) in the control groups
(Table 3). The forest plots demonstrate low heterogeneity in main
treatment effects; in each contributing study, SDD and SOD were
effective or showed a trend towards effectiveness compared to
control, with SDD being more effective than SOD. Estimates were
pooled using ﬁxed effects, resulting in aORs (95% CIs) for ICU
mortality of 0.74 (0.65e0.84) for SDD vs. control, 0.85 (0.73e1.00)
for SOD vs. control and 0.86 (0.78e0.94) for SDD vs. SOD (Table 3,
Fig. 4). With regard to the interaction effects, some heterogeneity
was present, with trends towards better effectiveness of SDD for
surgical patients compared to control in two studies and for med-
ical patients in the other two studies (I2 statistic 45%). For SOD vs.
control and SDD vs. SOD, the estimated interactions pointed in the
same direction in all studies. After ﬁxed effects pooling, there was
for both SDD and SOD, compared to control patients, a trend to-
wards higher effectiveness in surgical than in medical patients
(aROR (95% CI) 0.82 (0.62e1.08) and 0.83 (0.61e1.14)), but differ-
ences in effectiveness between the surgical and medical subgroups
were not statistically signiﬁcant (p of interaction term 0.15 and 0.25
respectively). Also for SDD vs. SOD, there was no interaction be-
tween treatment effect and admission type (aROR 0.89 (95% CI
0.74e1.08), p 0.25).
The aOR within medical and surgical patients indicate that
among surgical patients, the effect of SDD (and to a lesser extent
SOD) on ICU survival appeared to be stronger than the effects on
hospital survival (Table 3). Because these ratios are not based on
data coming from the same studies (four vs. three studies), we
performed an unplanned additional analysis among so-called ICU
survivors from the three studies that provided data for both
outcomes, which yielded a trend towards increased hospital
mortality among surgical patients who had been treated with
SDD and had survived their ﬁrst ICU admission (aOR 1.26 (95% CI
0.95e1.67), Supplementary Table 1) compared to control. How-
ever, this aOR was nonsigniﬁcant (p 0.11), as was the corre-
sponding interaction term, indicating this may also be a chance
ﬁnding. The opposite trend was observed for medical patients
receiving SOD, where the aOR (95% CI) tended to be lower for
hospital mortality (0.83 (0.68e1.01)) than for ICU mortality (0.93
(0.75e1.14)) (Table 3).
Discussion
In this individual patient data meta-analysis, the effects of both
SDD and SOD on hospital survival and ICU survival were not
modiﬁed by the type of ICU admission (surgical or medical). We
precisely quantiﬁed the effectiveness of these treatments in a large
population and conﬁrmed the recent ﬁndings that SDD is more
effective at improving hospital and ICU survival than SOD.
There was no effect modiﬁcation by admission type in any of
the three comparisons. Moreover, our ﬁndings provide further
evidence that SDD is more efﬁcacious than SOD in improving
patient survival [4]. SDD differs from SOD in the fact that in
addition to the oropharyngeal paste, patients are treated with a
gastrointestinal suspension (containing the same antibiotics) and
receive a 4-day course of third-generation cephalosporins, which
consisted of cefotaxime in 24 and ceftriaxone in ﬁve study cen-
tres. Both differences may contribute to the difference in
effectiveness.
Decontamination of the gastrointestinal tract may reduce the
risk of gut-derived sepsisdand thereby mortalitydthrough a
reduction in systemic translocation of pathogens from the gut [18].
In prior studies, SDDwasmore effective at preventing ICU-acquiredbacteraemia with Enterobacteriaceae than SOD, and rectal coloni-
zation with Gram-negative bacteria was associated with increased
risk of ICU-acquired bacteraemia with these pathogens [1,4,19].
Also, effective gastrointestinal decontamination may reduce res-
piratory colonization and infection with these pathogens, through
reductions in translocation via the gutelymph axis, (micro-)aspi-
ration and exogenous translocation [18]. In fact, SDDwas associated
with a statistically signiﬁcant reduction in the risk of respiratory
colonization with Enterobacteriaceae (and not with primarily res-
piratory pathogens such as Pseudomonas aeruginosa) compared to
SOD [20].
The 4-day course of cephalosporinsdincluded in the SDD
regimen with the aim to treat any incubating respiratory tract
infection before decolonization is achieveddmay also improve
outcome. Many patients enrolled onto the SOD and control groups
also received antibiotics during the ﬁrst days of ICU admission for
therapeutic reasons. An analysis of the original study data of de
Smet et al. [1] found that the proportion of SDD-treated patients
receiving intravenous antibiotics compared to SOD was 13% to 25%
higher between days 1 and 5, but lower from day 7 onwards (ab-
solute difference; Supplementary Table 2 and Supplementary
Fig. 3). The relative contribution of the gastrointestinal suspen-
sion vs. the 4-day course of intravenous cephalosporins to the
difference in effectiveness of SDD and SOD cannot be disentangled
from these data.
We observed that in surgical patients, SDD appeared more
effective at improving ICU survival than hospital survival, sug-
gesting that part of the beneﬁt from SDDwith regard to ICU survival
was lost before hospital discharge. An opposite trend was observed
amongmedical patients receiving SOD, with amore profound effect
of SOD on in-hospital mortality than on ICU mortality. Up front, we
chose hospital survival as our primary outcome because of its
clinical relevance. These ﬁndings provide further support for using
hospital mortality as the primary outcome in future studies.
Using individual patient data from 17 898 ICU admissions in 29
hospitals in three countries has several additional distinct beneﬁts
over performing a meta-analysis with aggregate data. Firstly, and
most importantly, it allowed us to assess interaction without the
risk of aggregation bias and with more statistical power [9]. Sec-
ondly, we created a database with transparent inclusion criteria
and adopted a uniform statistical analysis per study, correcting for
confounding where necessary. The quality of the data was high, as
many variables were provided with few missing data (<0.2%,
Table 1).
We performed a two-stage meta-analysisdas opposed to a
one-stage meta-analysis (OSM) in which all studies are analysed
together in one modeldbecause it allowed assessment of within-
trial-level interactions, thereby preventing aggregation bias
[9,21]. Although within-trial-level interactions may be estimated
separately from across-trial level interactions in an OSM (by
centring the covariate of interest per study), we considered that
this approach could not fully prevent bias in our data because the
three treatment arms are not represented in all studies. In
addition, a two-stage approach enabled correction for con-
founding by all relevant variables that were available within each
CRT, which would have required multiple imputation in an OSM.
Finally, the results of a two-stage meta-analysis are more easily
interpretable than the results of an OSM, with visualization of
the results per study in forest plots and the possibility to calcu-
late clinically meaningful odds ratios (ORs) from the interaction
terms.
This study also has limitations. Firstly, study selection was
limited to publications from 2000 onwards to enhance general-
izability of ﬁndings to today's practice, yet in the three smallest
studies, all patients were recruited between 1990 and 2000.When
N.L. Plantinga et al. / Clinical Microbiology and Infection 24 (2018) 505e513512we extended the search to studies that recruited patients from
1990 onwards, we identiﬁed two additional eligible studies from
which individual patient data were not available [22,23]. Three
RCTs altogether including 506 patients were excluded because
they recruited trauma patients only, which precludes assessment
of effect modiﬁcation by admission type. In one of these, the effect
of SDD on survival was assessed with an OR of 0.75 (95% CI
0.40e1.37) for late mortality compared to placebo [24]. Secondly,
all studies were performed in settings with low levels of antibiotic
resistance (Supplementary Table 3). This limits the generaliz-
ability of our ﬁndings to settings with <10% rectal colonization
with highly resistant microorganisms and <3% of methicillin-
resistant S. aureus and vancomycin-resistant enterococci. How-
ever, we also consider the absence of heterogeneity due to
different bacterial ecology a study strength. A cluster randomized
trial in ICUs with higher levels of antibiotic resistance has recently
been ﬁnalized (ClinicalTrials.gov identiﬁer NCT02208154).
Thirdly, any individual patient data meta-analysis relies on the
availability of original data and deﬁnitions used. Although we
obtained the original data from all studies identiﬁed, it was not
possible to recode the original deﬁnitions of surgical and medical
admissions to a single identical deﬁnition. The chosen deﬁnition,
using the criteria from the original studies, may have introduced
heterogeneity within the subgroups, thereby biasing the potential
difference in effectiveness between the subgroups towards null.
However, it also enhances generalizability to ICUs using different
deﬁnitions for admission type, thereby responding to the prag-
matic nature of the research question. Furthermore, we did not
account for competing events. We chose to perform a logistic
regression analysis because hospital survival is a clinically rele-
vant outcome, and we prefer the interpretation of ORs from lo-
gistic regression over hazards ratios that result from survival
analysis. We justify this choice because follow-up was complete
and differences in hospital discharge policy per study arm are not
to be expected. Finally, despite obtaining individual patient data
from all studies that met our inclusion criteria, our study may
have been underpowered to identify effect modiﬁcation. This may
have occurred for the comparison of SOD to controls, where >95%
of SOD patients were derived from a single study [1], which also
explains the wide CIs for the comparison of SOD-treated patients
with controls.Conclusions
On the basis of the individual data of 16 528 patients from six
randomized studies in settings with low levels of antibiotic resis-
tance, the effectiveness of SDD and SODwas notmodiﬁed by type of
ICU admission. SDD and SOD improved hospital and ICU survival
compared to standard care in both surgical and medical patients,
with SDD being more effective than SOD.Acknowledgements
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